Intrathecal Cytokine Synthesis in Inflammatory and Demyelinating Diseases of the Central Nervous System

  • Bruno Tavolato
  • Paolo Gallo
Part of the NATO ASI Series book series (NSSA, volume 258)

Abstract

The immune response is strictly and continuously regulated by a highly complex network of soluble mediators (i.e., cytokines and growth factors) that usually act as autocrine and/or paracrine regulators of cell growth and function. Under pathological conditions, however, when these mediators are produced in larger amounts in tissues or by circulating cells, they can be detected in biological fluids, and may exert hormone-like effects. Thus, the analysis of body fluids (such as serum, cerebrospinal fluid, urine and synovial fluid) for the presence of cytokines may constitute a strategy to define the role of these factors in inflammatory reactions in vivo.

Keywords

Hepatitis Migraine Dementia Interferon Integrin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbott, R.J., Bolderson, I., Gruer, P.J.K., and Peatfield, R.C., 1987. Immunoreactive IFN-7 in CSF in neurological disorders. J. Neurol.Neurosurg.Psychiat. 50: 882.PubMedCrossRefGoogle Scholar
  2. Adachi, A., Kumamoto., R., and Araki, S., 1989. Interleukin 2 receptor levels indicating relapse in multiple sclerosis. Lancet i: 559.Google Scholar
  3. Adachi, A., Kumamoto, R., and Arachi, S., 1990. Elevated soluble interleukin-2 receptor levels in patients with multiple sclerosis. Ann.Neurol 28: 687.PubMedCrossRefGoogle Scholar
  4. Baron, J.L., Madri, J.A., Ruddle, N.H., Hashim, G., Janeway, C.A. Jr., 1993. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp.Med. 177: 57.PubMedCrossRefGoogle Scholar
  5. Benveniste, E.N., Sparacio, S.M., Norris, J.G., Grenett, H.E., and Fuller, G.M., 1990. Induction and regulation of interleukin-6 gene expression in rat astrocytes. J. Neuroimmunol. 30: 201.PubMedCrossRefGoogle Scholar
  6. Bernard, J.T., Ameriso, S., Kempf, R.A., Rosen, P., Mitchell, M.S., Fisher, M., 1990. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 40: 154.PubMedCrossRefGoogle Scholar
  7. Brosnan, C.F., Selmaj, K.W., Raine, C.S., 1988. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J. Neuroimmunol 18: 87.PubMedCrossRefGoogle Scholar
  8. Cotran, R.S., Pober, J.S., Gimbrone, M.A., Springer, T.A. Jr., Wiebke, E.A., Gaspari, A.A., Rosemberg, S.A., and Lotze, M.T., 1987. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J. Immunol 139: 1883.Google Scholar
  9. Deckert-Schlüter, M., Schlüter, D., and Schwendemann, G., 1992. Evaluation of IL-2, SIL-2R, IL-6, TNFα, and IL-1ßlevels in serum and CSF of patients with optic neuritis. J. NeurolSci. 113: 50.CrossRefGoogle Scholar
  10. de Maeyer, E., and de Maeyer-Guignard, J., 1991. Interferons, in: “The Cytokine Handbook”, A. Thomson, ed., Academic Press Ltd., London.Google Scholar
  11. Denicoff, K.D., Rubinoff, D.R., and Papa, M.Z., 1987. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. lntern. Med. 107: 293.Google Scholar
  12. Dinarello, C.A., 1987. Interleukins, tumor necrosis factors (cachectin), and interferons as endogenous pyrogens and mediators of fever. Limphokines 14: 1.Google Scholar
  13. Dinarello, C.A., 1989. Interleukin-1 and its biologically related cytokines, Adv.Immunol. 44: 153.Google Scholar
  14. Dinarello, C.A., 1991. Interleukin-1, in: “The Cytokine Handbook”, A. Thomson, ed., Academic Press Ltd, London.Google Scholar
  15. Dinarello, C.A., and Wolff S.M., 1993. The role of interleukin-1 in disease, N. Engl.Med. 328: 106.Google Scholar
  16. Ellison, M.D., Krieg, R.J., Povlishock, J.T., 1990. Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions. J. Neuroimmunol 28: 249.PubMedCrossRefGoogle Scholar
  17. Ellison, M.D., and Merchant, R.E., 1991. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J. Neuroimmunol. 33: 245.PubMedCrossRefGoogle Scholar
  18. Fontana, A., Fierz, W., and Wekerle, H., 1984. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 307: 273.PubMedCrossRefGoogle Scholar
  19. Franciotta, D.M., Grimaldi, L.M.E., Martino, G.V., Piccolo, G., Bergamaschi, R., Citterio, A., and Melzi d’Eril, G.V., 1989. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann.Neurol 26: 787.PubMedCrossRefGoogle Scholar
  20. Frei, K., Siepl, C., Groscurth, P., Bodmer, S., Schwerdel., C., and Fontana, A., 1987. Antigen presentation and tumor cytotoxicity by interferon-gamma treated microglial cells. Eur.J. Immunol. 17: 1271.PubMedCrossRefGoogle Scholar
  21. Frei, K., Leist, T.P., Meager, A., Gallo, P., Leppert, D., Zinkemagel, R.M., and Fontana, A., 1988. Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients. J. Exp.Med. 168: 449.PubMedCrossRefGoogle Scholar
  22. Frei, K., Malipiero, U.V., Leist, T.P., Zinkemagel, R.M., Schwab, M.E., and Fontana, A., 1989. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur. J. lmmunol 19: 689.CrossRefGoogle Scholar
  23. Gallo, P., Piccinno, M.G., Pagni, S., and Tavolato, B., 1988. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann.Neuro/l 24: 795.CrossRefGoogle Scholar
  24. Gallo, P., Argentiero, V., Piccinno, M.G., Giometto, B., Pagni, S., Bozza, F., and Tavolato, B., 1989a. Soluble mediators of the immune response in cerebrospinal fluid and serum of patients with multiple sclerosis, in: “Multiple Sclerosis Research”, M.A. Battaglia, ed., Elsevier Science Publisher B.V. (Biomedicai Division), Amsterdam.Google Scholar
  25. Gallo, P., Frei, K., Rordorf, C., Lazdins, J., Tavolato, B., and Fontana, A., 1989b. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J. Neuroimmunol. 23: 109.PubMedCrossRefGoogle Scholar
  26. Gallo, P., Piccinno, M.G., Pagni, S., Argentiero, V., Giometto, B., Bozza, F., and Tavolato, B., 1989c. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and IFN gamma levels in serum and cerebrospinal fluid. J. Neurol.Sci. 92: 9.PubMedCrossRefGoogle Scholar
  27. Gallo, P., Piccinno, M.G., Krzalic, L., and Tavolato, B., 1989d. Tumor necrosis factor alpha (TNFα) and neurological diseases. Failure in detecting TNFαin the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumors. J. Neuroimmunol. 23: 41.PubMedCrossRefGoogle Scholar
  28. Gallo, P., Frei, K., Leppert, D., and Fontana, A., 1990. On the intrathecal synthesis of immunoglobulins: detection of BSF-2/IL-6 in CSF, in: “Trends in Neuroimmunology”, M.G. Marrosu, C. Cianchetti, and B. Tavolato, eds., Plenum Press, New York.Google Scholar
  29. Gallo, P., Giometto, B., and Tavolato, B., 1991a. Neuroimmunology of HIV-1 infection. Arch. AIDS Res. 5: 53.Google Scholar
  30. Gallo. P., Laverda, A.M., De Rossi, A., Pagni, S., Del Mistro, A., Cogo, P., Piccinno M.G., Plebani, A., Tavolato, B., and Chieco-Bianchi, L., 1991b. Immunological markers in the cerebrospinal fluid of HIV-1-infected children. Acta Paediatr.Scand. 80: 659.PubMedCrossRefGoogle Scholar
  31. Gallo, P., Piccinno, M.G., Tavolato, B., and Siden, A., 1991c. A longitudinal study on IL-2, sIL-2R, IL-4, and IFN gamma in multiple sclerosis CSF and serum. J. Neurol.Sci. 101: 227.PubMedCrossRefGoogle Scholar
  32. Gorczynski, M., and Keystone, E.J., 1986. Interleukin-1 activity in human cerebrospinal fluid, Immunol.Lett. 13: 231.PubMedCrossRefGoogle Scholar
  33. Greenberg, S.J., Marcon, L., Hurwitz, B.J., Waldmann, T.A., Nelson, D.L., 1988. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N. Engl.Med. 319: 1019.Google Scholar
  34. Grimaldi, L.M.E., Marino, G.V., Franciotta, D.M., Brustia, R., Castagna, A., Pristerà, R., and Lazzarin, A., 1991. Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann.Neurol. 29: 21.PubMedCrossRefGoogle Scholar
  35. Hartung, H.-P., Hughes, R.A.C., Taylor, W.A., Heininger, K., Reiners, K., and Toyka, K.V., 1990. T cell activation in Guillain-BarréSyndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 40: 215.PubMedCrossRefGoogle Scholar
  36. Hauser, S.L., Doolittle, T.H., Lincoln, R., Brown, R.H., and Dinarello, CA., 1990. Cytokine accumulation in CSF of multiple sclerosis: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40: 1735.PubMedCrossRefGoogle Scholar
  37. Helfgott, D.C., Tatter, S.B., Santhanam, U., Clarick, R.H., Bhardway, N., May, L.T., and Sehgal, P.B., 1989. Multiple forms of IFN-ß2/IL-6 in serum and body fluids during acute bacterial infection. J. Immunol. 142: 948.PubMedGoogle Scholar
  38. Hirsh, R.L., Panitch, H.S., and Johnson, K.P., 1985. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J. Clin.Immunol. 5: 386.CrossRefGoogle Scholar
  39. Houssiau, F.A., Bukasa, K., Sindic, C.J.M., Van Damme, J.V., and Van Snick, J., 1988. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin.Exp-Immunol.71: 320.PubMedGoogle Scholar
  40. Helle, M., Boeije, L., de Groot E., de Vos, A., and Aarden, L.A., 1991. Sensitive ELISA for interleukin-6.Detection of IL-6 in biological fluids: synovial fluids and sera. J. Immunol.Meth. 138: 47.CrossRefGoogle Scholar
  41. Hirano, T., 1991. Interleukin-6, in: “The Cytokine Handbook”, A. Thomson, ed., Academic Press, London.Google Scholar
  42. Kittur, S.D., Kittur, D.S., Soncrant, T.T., Rapoport, S.I., Tourtellotte, W.W., Nagel, J.E., and Adler, W.H., 1990. Soluble interleukin-2 receptors in the cerebrospinal fluid from individuals with various neurological disorders. Ann.Neurol. 28: 168.PubMedCrossRefGoogle Scholar
  43. Lebon, P., Schuller, E., Degos, J.-D., Lyon-Caen, O., and Ponsot, G., 1987. CSF alpha and gamma interferons in acute and subacute encephalitis and in multiple sclerosis: comparative study, in: “Cellular and Humoral Immunological Components of Cerebrospinal Huid in Multiple Sclerosis”, A. Lowenthal and J. Raus, eds., Plenum Press, New York.Google Scholar
  44. Lebon, P., Boutin, B., Dulac, O., Ponsot, G., and Arthuis, M., 1988. Interferon in acute and subacute encephalitis. Br.Med.J. 296: 9.CrossRefGoogle Scholar
  45. Leist, T.P., Frei, K., Kam-Hansen, S., Zinkernagel, R.M., and Fontana, A., 1988. Tumor necrosis factor a in cerebrospinal fluid during bacterial, but not viral meningitis. Evaluation in murine model infections and in patients. J. Exp. Med. 167: 1743.PubMedCrossRefGoogle Scholar
  46. Leppert, D., Frei, K., Gallo, P., Yasargil, M.G., Hess, K., Baumgartner, G., and Fontana, A., 1989. Brain tumor: detection of B-cell stimulatory factor-2/interleukin-6 in the absence of oligoclonal bands of immunoglobulins. J. Neuroimmunol. 24: 259.PubMedCrossRefGoogle Scholar
  47. Maimone, D., Gragory, S., Arnason, B.G.W., and Reder, A., 1991. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 32: 67.PubMedCrossRefGoogle Scholar
  48. Manogue, K.R., van Deventer, S.J.H., and Cerami, A., 1991. Tumor necrosis factor alpha or cachectin, in: “The Cytokine Handbook”, A. Thomson, ed., Academic Press, London.Google Scholar
  49. Mantovani, A., and Dejana, E., 1989. Cytokines as communication signals between leukocytes and endothelial cells. Immunol.Today 10: 370.PubMedCrossRefGoogle Scholar
  50. McClain, J., Cohen, D., Ott, L., Dinarello, CA., and Young, B., 1987. Ventricular fluid interleukin-1 activity in patients with head injury, J. Lab.Clin.Med. 110: 48.PubMedGoogle Scholar
  51. McCracken, G.H. Jr., Mustafa, M.M., Ramilo, O., Olsen, K.D., and Risser, R.C., 1989. Cerebrospinal fluid interleukin-1ßand tumor necrosis factor concentrations and outcome from neonatal gram-negative enteric bacillary meningitis. Pediatr.Infect.Dis.J. 8: 155.PubMedGoogle Scholar
  52. Mustafa, M.M., Lebel, M.H., Ramilo O., Olsen, K.D., Resch, J.S., Beutler, B., and McCracken, G.H. Jr., 1989a. Correlation of interleukin-1ßand cachectin concentration in cerebrospinal fluid and outcome from bacterial meningitis. J. Paediatr. 115: 208.CrossRefGoogle Scholar
  53. Mustafa, M.M., Ramilo, O., Olsen, K.D., Franklin, P.S., Hansen, E.J., Beutler, B., and McCracken, G.H., 1989b. Tumor necrosis factor in mediating experimental Haemophilus Influenzae type b meningitis. J. Clin.Jnvest. 84: 1253.CrossRefGoogle Scholar
  54. Nadal, D., Leppert, D., Frei, K., Gallo, P., Lamche, H., and Fontana, A., 1989. Tumor necrosis factor-αin infectious meningitis. Arch.Dis.Child. 64: 1274.PubMedCrossRefGoogle Scholar
  55. Nijsten, M.W.N., de Groot, E.R., ten Duis, HJ., Klasen, HJ., Hack, CE., and Aarden, L.A., 1987. Serum levels of interleukin-6 and acute phase responses. Lancet ii: 921.CrossRefGoogle Scholar
  56. Peter, J.B., Boctor, F.N., Tourtellotte, W.W., 1991. Serum and CSF levels of IL-2, sIL-2R, TNFa, and IL-lßin chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 41: 121.PubMedCrossRefGoogle Scholar
  57. Quagliarello, V.J., Wispelwey, B., Long, W.J., and Scheid, W.M., 1991. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat: characterization and comparison with tumor necrosis factor. J. Clin.Invest. 87: 1360.PubMedCrossRefGoogle Scholar
  58. Quagliarello, V.J., and Scheid, W.M., 1992. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N. Engl.Med. 327: 864.CrossRefGoogle Scholar
  59. Ramilo, O., Mustafa, M.M., Sáez-Llorens, X., Mertsola, J., Ohkawara, S., Yoshinaga, M., Hansen, EJ., and McCracken, G.H. Jr., 1989. Role of interleukin 1-beta in meningeal inflammation. Ped.Infect.Dis.J. 12: 909.CrossRefGoogle Scholar
  60. Ramilo, O., Sáez-Llorens, X., Mertsola, J., Jafari, H., Olsen, K.D., Hansen, E.J., Yoshinaga, M., Ohkawara, S., Nariuchi, H., and McCracken, G.H. Jr., 1990. Tumor necrosis factor a/cachectin and interleukin 1ßinitiate meningeal inflammation. J. Exp.Med. 172: 497.PubMedCrossRefGoogle Scholar
  61. Robbins, D.S., Shirazi, Y., Drysdale, B.-E., Lieberman, A., Shin, H.S., and Shin, M.L., 1987. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J. Immunol. 139: 2597.Google Scholar
  62. Saukkonen, K., Sande, S., Cioffe, C., Wolpe, S., Sherry, B., Cerami, A., and Tuomanen, E., 1990. The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J. Exp. Med. 171: 439.PubMedCrossRefGoogle Scholar
  63. Selmaj, K.W., and Raine, C.S., 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitto. Ann.Neurol. 23: 339.PubMedCrossRefGoogle Scholar
  64. Sharief, M.K., Hentges, R., and Thompson, EJ., 1991a. The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis. J. Neuroimmunol. 32: 43.PubMedCrossRefGoogle Scholar
  65. Sharief, M.K., Phil, M., and Hentges, R., 1991b. Association between tumor necrosis factor-a and disease progression in patients with multiple sclerosis. N. Engi.Med. 325: 467.CrossRefGoogle Scholar
  66. Shaskan, E.G., Thompson, R.M., and Price, R.W., 1992. Undetectable tumor nercrosis factor-alpha in spinal fluid from HIV-1-infected patients. Ann.Neurol. 31: 687.PubMedCrossRefGoogle Scholar
  67. Symons, A., Bundick, R.V., Suckling, A.J., and Rumsby, M.G., 1987. Cerebrospinal fluid interleukin-1-like activity during chronic relapsing experimental allergic encephalomyelitis. Clin.Exp.Immunol. 68: 648.PubMedGoogle Scholar
  68. Tsukada, N., Miyagi, K., Matsuda, M., Yanagisawa, N., and Kone, K., 1991. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 102: 230.CrossRefGoogle Scholar
  69. Van Meir, E., Sawamura, Y., Diserens, A.-C., Hamou, M.F., and de Tribolet, N., 1990. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 50: 6683.PubMedGoogle Scholar
  70. Van Oers, M.H.J., Van der Heyden, A.A.P.A.M., and Aarden, L.A., 1988. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin.Exp.Immunol. 71: 314.PubMedGoogle Scholar
  71. Vecht, C.J., Keohane, C., Menon, R.S., Henzen-Logmans, S.C., Punt., C.J.A., Stoter, G., 1990. Acute fatal leukoencephalopathy after interleukin-2 therapy. N. Engl.Med. 323: 1146.Google Scholar
  72. Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., and Espevik, T., 1989a. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp.Med. 169: 333.PubMedCrossRefGoogle Scholar
  73. Waage, A., Halstensen, A., Shalaby, R., Brandtzaeg, Kierulf, P., and Espevik, T., 1989b. Local production of tumor necrosis factor a, interleukin 1ß, and interleukin 6 in meningococcal meningitis. J. Exp.Med. 170: 1859.PubMedCrossRefGoogle Scholar
  74. Weiler, M., Stevens, A., Sommer, N., Melms, A., Dichgans, J., and Wiethölter, H., 1991. Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders. J. Neurol. Sci. 104: 215.CrossRefGoogle Scholar
  75. Wesselingn, S.L., Gough, N.M., Finlay-Jones, J.J., and McDonald, P.J., 1990. Detection of cytokine mRNA in astrocyte cultures using the polymerase chain reaction. Lymphok.Res. 9: 177.Google Scholar
  76. Yasukawa, K., Hirano, T., Watanabe, Y., Muratani, K., Matsuda, K., Nakai, S., and Kishimoto, T., 1987. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 6: 2939.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Bruno Tavolato
    • 1
  • Paolo Gallo
    • 1
  1. 1.Institute of Neurology, Second Neurologic ClinicUniversity of Padua, School of MedicinePaduaItaly

Personalised recommendations